Hepagene

Hepagene.com

ABOUT HEPAGENE

Non-alcoholic Steatohepatitis (NASH)

Chronic Hepatitis B Infection (HBV)

PIPELINE

Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH

About HPG1860

About NASH

About Hepagene Therapeutics, Inc

MANAGEMENT TEAM

INVESTORS
Morningside Venture Capital ("Morningside") is one of China's earliest early-stage venture investors with over US$ 1.5 billion under management, from the commitment of sovereign wealth funds,family offices, funds of funds, university endowment and other major investors. With a team that has worked together for almost 20 years, Morningside continues to discover, support and encourage entrepreneurs.
Loyal Valley Capital (LVC) is a thematic, research-driven private equity firm focused on deep fundamental research and unlocking value through post-investment value-creation. LVC manages capital on behalf of a geographically diversified group of long-term institutional investors, including sovereign wealth funds, private banks, family offices, and fund of funds managers, from across the Americas, Europe, and Asia.
Founded in 2015, Apricot Capital focuses on investment in innovative companies in life science industry. Apricot team has strong industry experience and deep insight in healthcare sectors and is quickly emerging as a leading biotech investor in China.

Oceanpine Capital is an institutional growth equity investment company formed by seasoned entrepreneurs and sophisticated investors with 20 years of in-depth industry operational and business building experiences in both China and the US. With a perspective of achieving successful growth over the long term, Oceanpine partners visionary entrepreneurs to build world-class companies together over a period of years rather than on the short-term impact.